Suven Life Sciences Ltd (Suven) is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2018, organized by Society for Neuroscience being held at San Diego, USA during 4 to 7 November 2018. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference.
Key pharmacology, ADME, Safety and Phase-2 clinical trial status of SUVN-502 (5-HT6 receptor antagonist), Phase 1 clinical data of SUVN-G3031 (Histamine-3 receptor antagonist) and SUVN-D4010 (5-HT4 receptor partial agonist) along with CB2 agonist and Muscarinic (M1) acetylcholine receptor positive allosteric modulators (PAM) to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer's, Schizophrenia, ADHD; Depression & Mood Disorders, Neuropathic Pain and Sleep Disorders are being be presented by Suven scientists at SFN-2018. These data presentations highlight Suven's continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.
Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.236.75 as compared to the previous close of Rs. 240.25. The total number of shares traded during the day was 76102 in over 1291 trades.
The stock hit an intraday high of Rs. 249 and intraday low of 234.15. The net turnover during the day was Rs. 18495485.